Bionano Genomics (BNGO) Non-Current Debt (2018 - 2021)

Bionano Genomics (BNGO) has 4 years of Non-Current Debt data on file, last reported at $14.9 million in Q1 2021.

• For the quarter ending Q1 2021, Non-Current Debt fell 12.39% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2021 stood at $14.9 million (down 12.39% YoY), and the FY2020 full-year result was $16.3 million, down 18.72% from the prior year.
• Non-Current Debt retreated to $14.9 million in Q1 2021, from $16.3 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.1 million in Q4 2019 to a low of $1.8 million in Q2 2020.
• A 4-year average of $13.2 million and a median of $16.3 million in 2020 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 122.44% in 2019 and plunged 90.55% in 2020, its largest moves.
• Tracing BNGO's Non-Current Debt over 4 years: stood at $9.0 million in 2018, then jumped by 122.44% to $20.1 million in 2019, then retreated by 18.72% to $16.3 million in 2020, then dropped by 8.94% to $14.9 million in 2021.
• Business Quant data shows BNGO's Non-Current Debt at $14.9 million in Q1 2021, $16.3 million in Q4 2020, and $1.8 million in Q3 2020.